AACR 2022: YH008, a PD-1-CD40 Bispecific Antibody, Inhibits Tumor Growth In Vivo Through PD-1-Dependent Activation of CD40 Signaling
Conclusions
The PD1-CD40 human bispecific antibody YH008 demonstrates:
• Activation of CD40 signaling in a PD1-dependent manner in vivo.
• Superior in vivo efficacy against B16F10 and PDL1-CD40 BsAb treatment.
• Increased percentage of CD8+ T cells and activation of dendritic cells in the tumor microenvironment.
• No signs of systemic toxicity when administered in high doses.
Related pipeline: Anti-PD-1/CD40 bispecific antibody YH008
